GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

NCT06435455 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation

Interventions

DRUG: GH21
DRUG: D-1553

Sponsor

Suzhou Genhouse Bio Co., Ltd.

Collaborators

[object Object]